GRALNasdaqServices-Medical LaboratoriesFiscal year ends December 31

GRAIL, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$122.42+4.61 (+3.91%)

Close on Oct 19, 2026

Market cap: $5.28B
P/E (TTM): –
Dividend yield: –

GRAIL, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2023-01-01
Revenue	147	126	93	56
Research & Development	196	322	339	330
Selling, General & Admin	276	368	363	296
Selling & Marketing	117	154	162	122
General & Administrative	159	214	200	174
Advertising Expenses	15	18	22	25
Total Costs & Expenses	709	2,315	1,608	5,498
Operating Income	-562	-2,189	-1,515	-5,443
Interest & Investment Income	29	27	7.95	1.74
Other Non-Operating Income	28	27	7.75	1.50
Asset Impairment Charges	28	1,421	718	4,700
Pretax Income	-535	-2,162	-1,508	-5,441
Income Tax Expense	-126	-135	-42	-42
Net Income	-408	-2,027	-1,466	-5,399
EPS (Basic)(per share)	-11.11	-63.54	-47.21	-173.89
EPS (Diluted)(per share)	-11.11	-63.54	-47.21	-173.89
Shares Outstanding (Basic, Weighted)(shares)	37	32	31	31
Shares Outstanding (Diluted, Weighted)(shares)	37	32	31	31
Provision for Credit Losses	0.33	0	0	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -338.4%
Net margin: -236.9%
Return on equity, FY2025: -16.1%

Financial strength

Current ratio: 10.95
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 66.6%

Valuation

P/E ratio: –
Price to sales: 31.94
Price to book: 2.08
Dividend yield: –